购物车
  • 全部删除
  • TargetMol
    您的购物车当前为空

Semaxinib

Rating icon 很棒
Semaxinib
产品编号 T2064Cas号 204005-46-9
别名 司马沙尼, SU5416

Semaxinib (SU5416) 是一种选择性的 VEGFR(Flk-1/KDR) 抑制剂,其 IC50=1.23 μM。

Semaxinib

Semaxinib

Rating icon 很棒
Semaxinib
纯度: 99.84%
产品编号 T2064 别名 司马沙尼, SU5416Cas号 204005-46-9

Semaxinib (SU5416) 是一种选择性的 VEGFR(Flk-1/KDR) 抑制剂,其 IC50=1.23 μM。

规格价格库存数量
5 mg
¥ 498
现货
10 mg
¥ 818
现货
50 mg
¥ 2,515
现货
100 mg
¥ 3,120
现货
大包装 & 定制
加入购物车
TargetMol 的所有产品仅用作科学研究或药证申报,不能被用于人体,我们不向个人提供产品和服务。请您遵守承诺用途,不得违反法律法规规定用于任何其他用途。
实验操作小课堂
常见问题解答
产品的溶解度是多少?
建议您先查询TargetMol官网、陶术官网,看该抑制剂的产品介绍,找到溶解度信息。如果没有相应信息,建议联系技术对该化合物的溶解度进行测定。
购买多次产品,发现颜色不同,怎么办?
首先请您确认批次,如果是同一个批次产品,请联系技术同事核查产品颜色。如果是不同批次,请您放心,颜色不同可能是生产工艺不同而造成的,生产过程中的操作、温度、时间等因素可能会影响产品的颜色。如果您对该批次有疑虑,可在官网下载相应的质检报告,我们是对产品质量负责的。
细胞实验中,抑制剂如何溶解?
用 DMSO 配置较高浓度母液,母液存于 -80℃,建议多分装几管,一周内使用的存于 4℃,避免反复冻融。实验时用 pbs、生理盐水、培养基、水这些稀释,细胞实验DMSO的终浓度不超过 0.1%。如果超过 0.1%,则需要在做预试验的时候,先进行溶剂阴性对照实验,排除溶剂对细胞的影响。
是否能直接用缓冲液对抑制剂 DMSO 母液做梯度稀释?
大部分情况下,都是可以溶解的。但有时,有机试剂直接加入水相介质时会析出。建议将抑制剂先以DMSO做梯度稀释,再将经过稀释的抑制剂加入缓冲液或细胞培养基。有些抑制剂甚至只有在其工作浓度下才能溶于水相。 比如细胞实验中希望终浓度为 1 μM 的话,可以把 10 mM 的 DMSO 母液用 DMSO 稀释到 1 mM,再吸 2 μL 加入到 2 mL 的生理盐水/PBS/细胞培液,终浓度即为 1 μM。 为避免药物析出,稀释前,可将母液和培养基 37℃ 预热,避免温度低造成严重析出。若稀释过程中出现化合物析出的情况,建议您采用超声加热的方法使其复溶。
小规格产品,收到瓶子后看不到任何东西?
由于产品规格小,粉末在运输过程中产生的静电导致过于分散,管壁和盖子上皆会粘着,您可以放心,离心后加入适量溶剂直接配制母液、充分溶解即可。
查看更多

"Semaxinib"的相关化合物库

选择批次:
纯度:99.84%
联系我们获取更多批次信息

产品介绍

生物活性
产品描述
Semaxinib (SU5416) is a potent and selective VEGFR2 inhibitor (IC50: 1.23 μM), 20-fold more selective for VEGFR than PDGFRβ, lack of activity against InsR, EGFR, and FGFR. Semaxanib reversibly inhibits ATP binding to the tyrosine kinase domain of vascular endothelial growth factor receptor 2 (VEGFR2), which may inhibit VEGF-stimulated endothelial cell migration and proliferation and reduce the tumor microvasculature.
靶点活性
VEGFR2:1.23 μM
体外活性
SU5416 inhibits VEGF-driven mitogenesis in a dose-dependent manner with an IC50 of 0.04±0.02 μM (n=3). In contrast, SU5416 blocked FGF-dependent mitogenesis of HUVECs with an IC50 of 50 μM (n=10). The selective activity of SU5416 on Flk-1 is supported by the fact that testing of SU5416 using NIH 3T3 cells overexpressing either the EGF or insulin receptors indicated a complete lack of activity (IC50>100 μM). This observation is confirmed by immunoblotting after ligand stimulation. An IC50 of 20.26±5.2 μM (n=7), which is about 20-fold less in potency on PDGF-dependent autophosphorylation, is observed when SU5416 is tested in NIH 3T3 cells overexpressing the human PDGF receptor β[1].
体内活性
Daily administration of SU5416 (i.p., 3 mg/kg/day) inhibits the local growth of C6 tumors in the colon. A comparable level of growth inhibition (62% by day 16; P=0.001) is observed for tumors growing in the colon in comparison with ones growing in the hindflank region (54% by day 18; P=0.001). These results indicate that SU5416 could inhibit tumor growth at a site other than the subcutaneous implantation site, where the preexisting vasculature may be different[1]. Daily treatment with SU5416(25 mg/kg) results in a significantly lower tumor growth rate with tumor masses of up to 8% of that present in control animals by day 22 after implantation. Inhibition of tumor growth is clearly preceded by a marked reduction of the tissue area covered by the newly formed glioma microvasculature in the SU5416-treated group, indicating a reduced initial tumor vascularization[2].
激酶实验
Solubilized membranes from 3T3 Flk-1 cells are added to polystyrene ELISA plates that has been precoated with a monoclonal antibody that recognizes Flk-1. After an overnight incubation with lysate at 4°C, serial dilutions of SU5416 are added to the immunolocalized receptor. To induce autophosphorylation of the receptor, various concentrations of ATP are added to the ELISA plate wells containing serially diluted solutions of SU5416. The autophosphorylation is allowed to proceed for 60 min at room temperature and then stopped with EDTA. The amount of phosphotyrosine present on the Flk-1 receptors in the individual wells is determined by incubating the immunolocalized receptor with a biotinylated monoclonal antibody directed against phosphotyrosine. After removal of the unbound anti-phosphotyrosine antibody, avidin-conjugated horseradish peroxidase H is added to the wells. A stabilized form of 3,3′,5,5′-tetramethyl benzidine dihydrochloride and Water2 is added to the wells. The color readout of the assay is allowed to develop for 30 min, and the reaction is stopped with H2SO4. Parallel biochemical kinase assays are performed to measure autophosphorylation on EGFR and fibroblast growth factor receptor[1].
细胞实验
SU5416 is dissolved in DMSO and stored,and then diluted with appropriate media (DMSO<0.5%) before use[1] 3T3Her2 and 488 g2M2 are NIH3T3 fibroblast cell lines engineered to overexpress Her2 and to express human PDGF-BB and human PDGF receptor β.Both cell lines are cultured in DMEM supplemented with 2% CS and 2 mM L-glutamine.C6,Calu 6,A375,A431,and SF767T are plated in their respective growth medium at 2×103 cells/100 μL/well in 96-well,flat-bottomed plates.SU5416 is serially diluted in media containing DMSO (<0.5%) and added to cultures of tumor cells 1 day after the initiation of culture.Cell growth is measured after 96 h using the sulforhodamine B method.IC50s are calculated by curve fitting using four-parameter analysis[1].
别名司马沙尼, SU5416
化学信息
分子量238.28
分子式C15H14N2O
CAS No.204005-46-9
SmilesC(=C1C=2C(NC1=O)=CC=CC2)C=3NC(C)=CC3C
密度1.256 g/cm3
储存&溶解度
存储Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
溶解度信息
DMSO: 2.38 mg/mL (10 mM), Sonication is recommended.
溶液配制表
DMSO
1mg5mg10mg50mg
1 mM4.1967 mL20.9837 mL41.9674 mL209.8372 mL
5 mM0.8393 mL4.1967 mL8.3935 mL41.9674 mL
10 mM0.4197 mL2.0984 mL4.1967 mL20.9837 mL

SCI 文献

计算器

  • 摩尔浓度 计算器
  • 稀释 计算器
  • 配液 计算器
  • 分子量 计算器

体内实验配液计算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:
TargetMol | Animal experiments比如您的给药剂量是 10 mg/kg ,每只动物体重 20 g ,给药体积 100 μLTargetMol | Animal experiments 一共给药动物 10 只 ,您使用的配方为 5% TargetMol | reagent DMSO+ 30%PEG300+ 5%Tween 80 + 60%Saline/PBS/ddH2O, 那么您的工作液浓度为 2 mg/mL
母液配置方法: 2 mg 药物溶于 50 μLDMSOTargetMol | reagent ( 母液浓度为 40 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:50μLDMSOTargetMol | reagent 母液,添加 300 μLPEG300TargetMol | reagent 混匀澄清,再加 50μLTween 80, 混匀澄清,再加 600μLSaline/PBS/ddH2OTargetMol | reagent 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

1 请输入动物实验的基本信息
mg/kg
g
μL
2 请输入动物体内配方组成,不同的产品配方组成不同,如有配方需求,可先联系我们提供正确的体内配方。
% DMSO
%
% Tween 80
% Saline/PBS/ddH2O

剂量转换

对于不同动物的给药剂量换算,您也可以参考 更多

参考文献

文献引用

关键词

评论列表

4个月前
5.0
Rating icon 很棒

评论内容

Related Tags: buy Semaxinib | purchase Semaxinib | Semaxinib cost | order Semaxinib | Semaxinib chemical structure | Semaxinib in vivo | Semaxinib in vitro | Semaxinib formula | Semaxinib molecular weight